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Summary 
Background: Up until now there have been contradictory
data about the association between p.Val158Met catechol-
O-methyltransferase (COMT) polymorphism and risk of
preeclampsia (PE). The goal of this study was to assess the
potential correlation between p.Val158Met COMT poly-
morphism and risk of early-onset PE, risk of a severe form
of early-onset PE, as well as risk of small-for-gestational-
age (SGA) complicating PE.
Methods: The study included 47 early-onset PE patients and
47 control cases. Forty-seven early-onset PE patients were
grouped by disease severity (33 patients with a severe form
and 14 patients without severe features) and secondly by size
for gestational age (12 patients with appropriate-for-gestatio -
nal-age (AGA) and 35 patients with SGA size). p.Val158Met
polymorphism was genotyped by PCR-RFLP analysis. 
Results: Allele analysis showed significant difference in
COMT allele distribution between early-onset PE and con-
Kratak sadr`aj
Uvod: Do sada su postojali kontradiktorni podaci o pove -
zanosti polimorfizma p.Val158Met katehol-O-metiltrans-
feraza (COMT) i rizika od pojave preeklampsije (PE). Cilj
ove studije je bio da se utvrdi potencijalna povezanost
izme|u p.Val158Met COMT polimorfizma i rizika od razvo-
ja rane PE, te{kog oblika rane PE, kao i rane PE sa zasto-
jem u rastu (SGA).
Metode: Studija je obuhvatila 47 pacijentkinja sa ranom PE
i 47 kontrolnih subjekata. ^etrdeset sedam pacijentkinja sa
ranom PE su bile podeljene na osnovu te`ine oboljenja (33
pacijentkinje sa te{kim oblikom i 14 pacijentkinja sa odsus -
tvom te{kog oblika) i sekundarno na osnovu veli~ine za od -
 govaraju}u gestacionu starost (12 pacijentkinja sa odgo-
varaju}om veli ~inom novoro|en~adi za gestacionu starost i
35 pacijentki nja sa manjom veli~inom novoro|en~adi za
gestacionu sta rost). Polimorfizam p.Val158Met je odre|en
analizom PCR-RFLP. 
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Introduction
Preeclampsia (PE), a hypertensive disorder in
pregnancy, affects 3–8% of pregnancies worldwide. It
is the leading cause of maternal and fetal morbidity
and mortality (1–6). The exact pathogenesis of PE is
still unclear and different mechanisms have been pro-
posed in order to clarify it more precisely (7, 8). By
analyzing epidemiological data, it has been empha-
sized that genetic factors are one of the main risk fac-
tors for PE development and numerous candidate
gene studies and linkage analyses have been carried
out in this area (9). 
Recently, one of the genes whose expression
showed potential as a candidate gene for PE has been
the catechol-O-methyltransferase (COMT) gene (10).
COMT is among the major enzymes responsible for
inactivation of catechol-estrogens, which play an
important role in pregnancy management and fetal
development. One of the functional polymorphisms in
the COMT gene is the presence of G instead of A
base (rs4680) causing the positioning of the amino
acid methionine instead of valine at codon 158, and
thereby decreasing COMT activity (11, 12). Different
studies showed association between p.Val158Met
COMT polymorphism and an increased risk of PE in
different patient groups (11, 13). More recently, it
was shown that fetal p.Val158Met COMT polymor-
phism correlated with increased risk of PE, and mater-
nal p.Val158Met COMT poly morphism showed a pro-
tective role (14). 
According to the authors’ knowledge, there is
no study investigating the link between p.Val158Met
COMT polymorphism and the increased risk of PE in
the populations of the Balkan Peninsula, the Serbian
population in clu ded. Also, there is no known study
in vestigating the possible association between
p.Val158Met COMT poly mor phism and very early-
onset PE. Early-onset PE seems to be a placen ta-
mediated complication and is associated with ab -
normal uterine artery Doppler flow, fetal growth
restriction and adverse outcomes in mothers as well
as in fetuses (15). 
The aim of this study was to examine the poten-
tial correlation between p.Val158Met COMT poly-
morphism and the risk of early-onset PE, the risk of
severe form of early-onset PE and risk of small-for-
gestational-age (SGA) complicating PE in the Serbian
population. 
Materials and Methods 
Subjects
The study was conducted at the Clinic of
Gynecology and Obstetrics, Clinical Center of Serbia,
in the period between September 2012 and
December 2013. Official approval for this study was
obtained from the Ethics Committee of the Clinical
Center of Serbia. All patients and control subjects
were informed beforehand about this study and they
provided their written informed consent to participate. 
In a total of 94 participants, there were two
groups of patients: an early-onset PE group with 47
patients (50%) and 47 controls (50%). The early-
onset PE group was divided into two subgroups:
severe form of early-onset PE with 33 cases and mild
form of early-onset PE with 14 cases. Six patients with
HELLP syndrome were included in the severe form of
early-onset PE subgroup. Based on the second criteri-
on, all 47 early-onset PE patients were divided in two
subgroups, the AGA subgroup with 12 patients and
the SGA subgroup with 35 patients. Significant differ-
ences were observed between these two groups in
maternal age, body mass index (BMI), systolic and
diastolic blood pressure (BP) and in gestational age at
delivery. There was a significantly higher risk of SGA
neonate delivery in patients with early-onset PE.
Clinical characteristics of examined patients and con-
trols can be seen in Table I. 
PE, early-onset PE and severe PE were defined
according to the American College of Obstetricians
trol group as well as early-onset PE SGA and controls
(p=0.04057 and p=0.0411 respectively). A statistically
significant distribution difference between the severe form
and form without severe features of early-onset PE patients
was not observed (p>0.05). The highest difference ob -
served was in the allele recessive model where COMT
MetMet genotype was associated with decreased risk of
early-onset PE (OR=0.281; 95%CI=0.092–0.7836) and
PE complications including severe early-onset PE (OR=
0.304; 95%CI=0.086–0.944) and SGA early-onset PE
(OR=0.284; 95%CI=0.081–0.874).
Conclusions: COMT may be used as a candidate gene for
early-onset PE and its severe form and SGA complications.
Keywords: COMT, polymorphism, early-onset pre eclamp -
sia, severe, SGA
Rezultati: Alelska analiza pokazala je zna~ajnu razliku u dis-
tribuciji COMT alela izme|u pacijentkinja sa ranom PE i
kontrola kao i pacijentkinja sa ranom PE i SGA i kontrola
(p=0,04057, odnosno p=0,0411). Nije uo~ena statisti~ki
zna~ajna razlika u distribuciji izme|u te{ke forme PE i
forme PE bez te{kih karakteristika (p>0,05). Najzna~ajnija
razlika uo~ena je u alelskom recesivnom modelu gde je
COMT MetMet genotip bio povezan sa smanjenim rizikom
od pojave rane PE (OR=0,281; 95%CI=0,092–0,7836) i
komplikacija PE uklju~uju}i te{ku formu rane PE (OR=
0,304; 95%CI=0,086–0,944) i rane PE komplikovane zas-
tojem u rastu (OR=0,284; 95%CI=0,081–0,874).
Zaklju~ak: COMT bi mogao da se koristi kao gen kandidat
za pojavu rane PE i njenih komplikacija, te{kog oblika i zas-
toja u rastu.
Klju~ne re~i: COMT, polimorfizam, rana preeklampsija,
te{ka, zastoj u rastu
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and Gynecologists Task Force on Hypertension in
Pregnancy (5). HELLP syndrome was defined when
three of the following criteria were positive in the
absence of other pathologic conditions: lactate dehy-
drogenase (LDH) > 600 U/L, aspartate aminotrans-
ferase (AST) > 70 U/L or alanine aminotransferase
(ALT) > 70 U/L, and platelet count < 100,000
cells/mm (6). 
SGA and AGA were defined as birth weight
below the 10th percentile and birth weight between
the 10th and 90th percentile, respectively, according
to the national birth weight distribution of the Serbian
population (16). The excluding criteria were any of
the following: pregnant women with known abnormal
fetal karyotype or chromosomal abnormalities, multi-
fetal gestation, gestational hypertension without pro-
teinuria, chronic hypertension, diabetes mellitus, car-
diovascular disease, autoimmune disease and renal
disease. 
The control subjects were defined as healthy sin-
gleton pregnancies, having come to the Clinical
Center of Serbia for delivery, and delivering a healthy
neonate at term (37 weeks of gestation or more)
without medical or obstetric complications. 
Antenatal care protocol 
Antenatal care was provided according to hospi-
tal guidelines and protocols. At presentation, all
patients gave a detailed medical history and under-
went a general physical examination, which included
detection of edema, new onset of cerebral or visual
disturbances and presentation of pulmonary edema.
BMI was calculated by dividing the weight (kg) by the
square of height (m2). BP was measured in the sitting
position on the right arm after a 10-min rest, and the
first and fifth phases were recorded. Gestational age
was assessed based on ultrasound measurement.
Laboratory analyses were done in the morning after
at least 12 h of fasting. Creatinine, total bilirubin,
LDH, AST and ALT were measured by colorimetric
methods. Platelets were determined by impedance
measurement. One aliquot of analyzed EDTA-whole
blood was kept frozen at –70 °C for DNA extraction
and genotyping (no additional blood collection was
performed). Proteins in 24-h urine were measured by
the colorimetric method, with Pyrogallol red. In cases
where there was no time for 24-h urine collection or
an inadequate procedure for 24-h urine collection
was applied, a visual dipstick reading was performed.
At delivery, the type of delivery was recorded; gesta-
tional age was calculated; birth weight was measured;
and the Apgar score was assessed. 
DNA extraction and genotyping
Isolation of genomic DNA from 200 mL of
peripheral blood was done with the commercial kit for
isolating genomic DNA (Roche Diagnostics), in
accordance with manufacturer’s instructions. The de -
tection of variant presence in the gene p.Val158
Met COMT was performed by chain reaction amplifi-
cation of DNA. It was carried out in a 25 mL mixture
volume containing: a 12.5 mL QIAGEN Multiplex PCR
Table I Clinical characteristics of examined patients and controls.
Controls n=47
Early-onset PE 
n=47 (p)
Severe 
early-onset PE
n=33 (p)
Mild 
early-onset PE
n=14 (p)
Early-onset 
PE SGA
n=35 (p)
Early-onset 
PE AGA
n=12 (p)
Age (years) 29.44±4.49
32.14±5.52
(0.009767)
32.45± 5.22
(0.007997)
31.42±6.3
(0.2244)
32.06±6.09
(0.03021)
32.41±3.55
(0.03643)
Gestational age
(days)
275±9
225±28
(1.346 × 10-14)
218±23
(3.142 × 10-15)
241±33
(2.398 × 10-5)
219±24
(5.357 × 10-14)
240±34
(2.119 × 10-6)
BMI (kg/m2) 24.16±4.11
27.77±3.93
(0.0002266)
27.9±4.25
(0.0007854)
27.46±3.18
(0.01384)
27.0±3.37
(0.003876)
30.03±4.71
(0.0007481)
Systolic  BP
(mmHg)
108.62±9.9
162.98±18.61
(3.456 × 10-13)
171.36±15.07
(1.037 × 10-11)
143.21±8.23
(1.758 × 10-7)
163.57±18.92
(8.828 × 10-12)
161.25±18.35
(4.39 × 10-7)
Diastolic BP
(mmHg)
70.17±8.5
104.36±11.68
(3.898 × 10-13)
109.24±9.36
(9.147 × 10-12)
92.86±8.02
(3.333 × 10-7)
104.57±11.14
(7.54 × 10-12)
103.75±13.67
(8.559 × 10-7)
Proteinuria 
(g/24h)
/ 3.74±4.05 4.59±4.41 1.73±2.0 4.31±4.12 2.07±3.49
Birth weight (g) 3340.24±445.28
1511.3±784.2
(1.853 × 10-13)
1304.5±536.2
(1.918 × 10-13)
1998.6±1050.8
(8.639 × 10-5)
1206.3±450.3
(7.715 × 10-14)
2400.8±886.5
(0.0005678)
kit, 100 ng of isolated genomic DNA and 10 pmol
sense and antisense primers. Sense (P1) and anti-
sense (P2) primers were 5’-ACT GTG GCT ACT CAG
CTGTG-3’ and 5’-CCT TTT TCC AGG TCT GAC AA-
3’ respectively. 
The amplification was carried out in a PCR
instrument (Termocycler-in) GeneAmp PCR System
9700 (Applied Biosystems). Terms of PCR reactions
were as follows: denaturation at 94 °C 5 min; 30
cycles of amplification consisting of denaturation at
94 °C for 30 s, primer binding (annealing) at 66 °C
for 30 s and elongation at 72 °C for 1 min. The final
elongation was carried out at 72 °C for 5 min. The
product of PCR reactions consisted of 169 bp and
included the investigated polymorphism p.Val158Met.
The digestion amplification product, enzyme NlaIII
(Hin1II Thermo SCENTIFIC), was used. Electro -
phoretic separation was performed on 2.5% agarose
gel, containing ethidium bromide. In the case of the
unmodified (wild type) Val allele, enzyme cuts the
PCR product into fragment lengths of 114 bp, 29 bp
and 26 bp. In the case of the variant allele, Met
enzyme cuts the PCR product into fragment lengths
of 96 bp, 29 bp, 26 bp and 18 bp. After di gestion,
the enzyme fragments were visualized under ultravio-
let light transillumination (Wilber Lourmat). 
Statistical analysis
General clinical characteristics between cases
and controls were compared using Student’s t-tests or
Wilcox rank sum test where appropriate. Genotype
frequencies were tested against the theoretical Hardy-
Weinberg equilibrium (HWE) by c2 contingency table
analysis (degree of freedom = 2). Allele and geno-
type frequencies were compared between all cases of
PE and their controls by contingency tables or by the
Fisher’s exact probability test, and odds ratios (OR)
and 95% confidence intervals (CI) were computed.
The frequency of homozygotes for the common allele
was considered as the reference for comparisons (OR
= 1). Under a dominant model and a rare allele fre-
quency of 0.34, our study sample had a power 1-b =
0.78 to detect a genetic effect resulting in an OR =
0.2 at a type I error of 0.05. Power calculations were
performed in the online tool Genetic Power Calcu -
lator (17). 
Polymorphism was included in logistic regres-
sion models to be adjusted for clinical co-variables. 
All the computation was done in R language
and environment, version 3.1.0 (18). 
Results
Genotype analysis indicated that the difference
between the two investigated groups was at the con-
ventional level of significance. In order to estimate
allelic relative risks, allele-based parameterizations on
risk parameters were proposed. Allelic expression
analysis showed a statistically significant difference in
allele distribution between early-onset PE, early-onset
PE SGA and controls. In patients with early-onset PE,
Met allele was associated with 1.9 times lower risk of
developing early-onset PE, showing a protective role.
Similar situation was noted with early-onset PE SGA.
In patients with early-onset PE complicated by SGA,
Met allele was associated with 1.93 times lower risk
of early-onset PE SGA development. Regarding the
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Table II Distribution of COMT alleles, COMT allele dominant model and COMT allele recessive model in the investigated group
of early-onset preeclampsia patients and control group.
Controls 
(n)
Early-onset PE
OR (n) 
Severe 
early-onset PE 
OR (n)
Mild 
early-onset PE
OR (n)
Early-onset PE
SGA 
OR (n)
Early-onset PE
AGA
COMT
(genotype)
Wild type (10) (13) (10) (3) (10) (3)
Heterozygous (17) 1.173 (26)* 1 (17) 1.74 (9) 1.115 (19) 1.361 (7)
Homozygous (20) 0.315 (8)** 0.308 (6) 0.345 (2) 0.308 (6) 0.345 (2)
COMT
(allelic)
Val (37) (52) (37) (15) (39) (13)
Met (57) 0.526 (42)*** 0.511 (29) 0.565 (13) 0.518 (31)**** 0.552 (11)
COMT
(under AD
assumption)
Val-Val (10) (13) (10) (3) (10) (3)
Met-Met and
Met-Val (37) 0.709 (34) 0.625 (23) 0.991 (11) 0.679 (25) 0.814 (9)
COMT
(under AR
assumption)
Val-Val and Met-
Val (27) (39) (27) (12) (29) (10)
Met-Met (20) 0.281 (8)***** 0.304 (6)****** 0.229 (2) 0.284 (6)******* 0.275 (2)
*p=0.797; ** p=0.052; ***p=0.04057; ****p=0.0411; *****p=0.01235, Fisher exact test; ******p=0.02928;
*******p=0.01732
allele distribution difference between the two sub-
groups of early-onset PE patients, mild and severe
form of PE, there was no difference between these
two subgroups at the conventional level of signifi-
cance (Table II). 
Further introducing the allelic dominant and the
allelic recessive model, a more detailed analysis was
applied. In the allelic dominant model, the Met-Met
and Met-Val genotypes did not show any statistically
significant distribution difference between early-onset
PE, severe form of early-onset PE, early-onset PE SGA
and control subjects. In the allelic recessive model,
the COMT MetMet genotype showed a statistically
significant distribution difference between early-onset
PE, severe form of early-onset PE, early-onset PE SGA
and controls. The COMT MetMet genotype showed a
protective role, by decreasing the risk of early-onset
PE and its complications, including severe early-onset
PE and SGA early-onset PE. The risk was more
markedly decreased for SGA early-onset PE and, gen-
erally, the most markedly decreased for early-onset PE
(Table II). 
Finally, COMT locus was investigated together
with age and BMI in a multivariate logistic regression
analysis for assessment of potential association with
the total early-onset PE development. Age and BMI
were associated with approximately 1.1 times higher
risk of early-onset PE development. In COMT Met
homozygous subjects a protective role was shown by
reducing the risk for early-onset PE development 3.2
times. This effect remained even after age and BMI
adjustment (Table III). 
Discussion 
Precise and early recognition of high risk
patients may contribute to better management of PE
patients. Special focus should be placed on early-on -
set PE, since the risk of adverse maternal and perina-
tal outcome increases significantly when preeclamp-
sia develops early (19, 20). An epidemiological study
(21) has indicated that PE has a strong genetic com-
ponent to its occurrence, with additional geographic,
socio-economic and racial risk factors. Many genes
and their polymorphisms have been investigated as
gene candidates for susceptibility to preeclampsia
(22–24). 
Recently, one of the genes whose expression
showed the potential to be used as a PE candidate
gene was a COMT gene (10). COMT is one of the key
enzymes involved in catechol estrogen inactivation
(25). During pregnancy, significant increase in cate-
chol estrogen production has been detected, poten-
tially due to the increased activity of the placenta.
Placenta shows high activity of estrogen 2-hydroxy-
lase which produces 2-hydroxyestradiol and 4-hydrox-
yestradiol and the COMT enzyme which converts
them into 2-metoxyestradiol (2-ME). In the presence
of COMT, 2-ME suppresses hypoxia-inducible factor
1a (HIF-1a) accumulation and the production of sol-
uble fms-like tyrosine kinase 1 (sFlt-1) (26, 27). It was
suggested that during the PE, COMT is showing lower
activity which leads to the lower production of 2-ME,
accumulation of HIF-1a and increased production of
sFlt-1 (28). Recently, the animal COMT mice knock-
out model has been shown to be useful in clarifying
the significance of decreased COMT expression in
PE. In COMT-/- mice increased concentration of HIF-
1a induces an increased production of sFlt-1 thus
causing an inflammatory reaction and endothelial
dysfunction (10). A functional single-nucleotide poly-
morphism which codes the synthesis of membrane-
bound COMT results in a valine to methionine variant
at position 158 (p.Val158Met) rs4680 and decreased
COMT activity (29). Different studies that have been
recently published showed a correlation between
COMT genotypes and the risk of developing PE in dif-
ferent populations. Lim et al. (13) and Liang et al.
(11) showed association between COMT
p.Val158Met polymorphism and an increased risk of
PE and SGA in the Korean and Asian population
respectively. Regarding available data related to
European populations, Roten et al. (30) showed a
correlation between p.Val158Met genotype and re -
current PE. However, a link between the p.Val158Met
genotype and non-recurrent PE was not shown. Re -
cently, in a more detailed analysis, Hil et al. (14)
showed that maternal ACCG haplotype which is asso-
ciated with lower COMT activity was in correlation
with decreased PE risk. Explanation could be found in
the hypothesis proposed by Hill et al. (14) which con-
siders the idea that decreased maternal COMT activ-
ity has a protective role by stimulating the placenta to
produce 2-ME. Placental low COMT activity is the key
contributor to PE development. In our study and the
targeted subject-patient population, the COMT Met -
Met genotype in the allelic recessive model showed a
protective role by decreasing the risk of early-onset PE
3.2-fold. This effect remained even after age and BMI
adjustment. 
Regarding the potential of the p.Val158Met
genotype to do the risk stratification of PE, thus to dif-
ferentiate between mild and severe forms, there are
only limited data available. This study showed that
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Table III Multinomial logistic regression including age, BMI
and COMT polymorphisms.
Variable / 
polymorphism 
Early-onset PE
adjusted OR
(95%CI) 
Early-onset PE
p-value
Age (years) 1.122(1.015–1.253) 0.030064
BMI 1.134(1.133–1.568) 0.000876
COMT 
(AR model)
0.308
(0.091–0.960) 0.047627
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pregnancies with MetMet genotype had a lower risk
of developing severe forms of PE. Contrary to this,
Lim et al. (13) showed that the MetMet genotype was
associated with an increased risk of developing a
severe form of PE. Liang et al. (11) could not find sta-
tistical significance between severe and mild PE geno-
type and allele distribution. Our data are further sup-
ported by the distribution of COMT genotype which is
in HWE. Further studies with bigger sample size are
necessary to clarify the contradictory data. 
Further interesting and promising data could be
found regarding the potential association of COMT
genotype with SGA PE or SGA itself. There is growing
evidence that maternal and fetal genetic factors may
play an important role in SGA development. Cyto -
chrome P450 1A1 gene (CYP1A1), glutathione S-
transferase T1 (GSTT1) and insulin-like growth fac-
tor-I (IGF-I) were some of the proposed genetic
factors whose polymorphisms were found to be asso-
ciated with SGA (31, 32). In this study, we showed
that SGA early-onset PE patients have significantly dif-
ferent COMT allele distribution in comparison to con-
trol subjects. In the recessive allelic model, MetMet
decreased the risk of SGA early-onset PE 3.52 times.
Sata et al. (33) showed opposite data, that patients
with homozygous COMT-L alleles had 2.98 times
higher risk of low birth weight (<2500 g). It was con-
cluded that lower COMT activity might lead to the
accumulation of catechol estrogens due to its inabili-
ty to inactivate them, and, consequently, cause oxida-
tive DNA damage (34–36). Oxidative DNA damage
at the end of pregnancy might be associated with
SGA (37). Possible explanation of our data could be
the consideration that decreased maternal COMT
activity has a protective role by stimulating the placen-
ta to produce 2-ME. Placental low COMT activity is
the key contributor to PE development. 
The main weakness of our study was the limited
number of investigated patients, but we were primari-
ly focused on the difficult cases of early-onset PE (33
severe early-onset PE patients in comparison to 47
early-onset PE patients in total) with systolic BP
162.9±19.0 mm Hg and diastolic BP 104.6±11.9
mm Hg. 
Our data support the hypothesis established by
Hill et al. (14) in an early-onset PE patient population.
Further prospective studies in larger and ethnically
diverse populations are needed in order to confirm
the hypothesis as well as to identify the mec hanisms
behind it (38). 
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